
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is supported by a large, underpenetrated insulin-delivery market and a product portfolio that can drive multiple growth levers simultaneously, including the t:slim X2, the newly launched smaller Mobi pump, the planned Sigi tubeless patch pump, and continued Control-IQ automation enhancements. The company’s improving execution is reinforced by in-line revenue with gross margins that have exceeded consensus, full-year expectations of $1.065–$1.085B in revenue, 56–57% gross margin, and 5–6% EBITDA margin, while the pharmacy-channel shift should improve lifetime customer value to about $17K versus $8K from DME and support margin expansion over time. With roughly three-quarters of revenue from the US, over 150,000 OUS patients representing a potential $100M+ annual renewal opportunity, and Mobi Tubeless slated for a 2H’26 launch and late 2026 FDA approval timing, the company has a visible path to faster growth and a stronger profitability profile that appears underappreciated by the market.
Bears say
Tandem Diabetes Care is challenged by a business mix that still depends heavily on upfront durable-pump revenue even as it shifts to a Pay/Go model, creating near-term pressure from $0 upfront shipments and execution risk around converting patients into the pharmacy channel, where management itself notes the economics are better but adoption is still early. The bearish case is further supported by the company’s relatively modest scale and profitability profile, with the stock cited at just 1.3x EV/Sales and implied 2026-2030 margins still below the more optimistic long-term goals, which leaves downside if growth or pricing benefits fail to materialize as expected. Although record Q2 pump shipments of 22K, 10% of U.S. sales through pharmacy, and 45% formulary coverage show momentum, the market still appears to be underestimating the risk that the transition temporarily suppresses revenue before benefits from recurring supplies, international renewals, and new products like Mobi Tubeless are fully realized.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares